Global Monkeypox (Mpox) Market Assessment, By Treatment Type [Vaccine, Therapeutic], By Route of Administration [Oral, Injectable], By Distribution Channel [Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others], By Region, Opportunities and Forecast, 2017-2031F

Global monkeypox (Mpox) market is projected to witness a CAGR of 10.33% during the forecast period 2024-2031, growing from USD 185.90 million in 2023 to USD 408.16 million in 2031. The market demand for Mpox is anticipated to thrive drastically in the forecast years due to the rising prevalence of monkeypox disease, advancement in diagnostic technology, public health awareness, and the growing interest of investors in the development of monkeypox vaccines and therapeutics.

Mpox is a viral infection within the Orthopoxvirus genus, causing symptoms such as skin rash, mucosal lesions, fever, headache, muscle pain, fatigue, and swelling of the lymph nodes that last for two to four weeks. Growing awareness due to outbreaks and public health programs has increased demand for diagnostics, therapeutics, and preventive measures. Advances and regulatory approvals of effective vaccines further spur the market, and accelerated vaccine campaigns are foreseen to propel the market ahead in the forecast period due to the increasing disease burden. For instance, in January 2023, Becton, Dickinson and Company (BD) and Certest Biotec, S.L. received an Emergency Use Authorization (EUA) approval from the U.S. Food and Drug Administration (FDA) for the VIASURE Monkeypox Virus Real-Time polymerase chain reaction (PCR) reagent. The EUA allows for timely Mpox detection, supporting disease control efforts in the United States.

Increase in the Incidences of Monkeypox (Mpox) Disease

The incidence of monkeypox disease has become a terrific public health concern because recent outbreaks have occurred in areas other than the traditional endemic zones. Initially restricted to Central and West Africa, this infection has seen a rise in cases worldwide, partially due to increased human-animal contact, environmental changes, and world travel. The sharp rise in infections has incited health authorities to heighten vigilance and response efforts, thereby creating public awareness and a sense of urgency over the disease. It places an increased demand for appropriate diagnostics, vaccines, and treatments as a robust public health strategy is paramount in managing and mitigating monkeypox. This new epidemiology requires preparation in how one responds to emerging infectious diseases in an increasingly interconnected world. For instance, in August 2024, UTime Limited completed the acquisition of the Bowen Therapeutics laboratory of Bowen Therapeutics Inc. at UMASS Medical School to cater to the need for an effective monkeypox vaccine. Monkeypox, as such, is an infectious disease caused by the monkeypox virus.

Demand for Vaccines and Treatment for Monkeypox Disease to Drive Market Growth

The rising demand for vaccines and new treatments for monkeypox is mainly driven by increased awareness that the virus could spread more widely than people thought, posing risks to public health. This awareness encourages more research and development to find effective ways to prevent and treat the disease. The recent outbreaks highlighted the need for proper preventive measures and resulted in vaccination programs at governmental and health organizations. This growing urgency drives pharmaceutical companies, researchers, and public health officials to collaborate and perform research and developmental activities to deliver novel products. In general, the focus is on the accessibility of vaccines, alternatives for treatment, infection control, and preparing the world to face emerging infectious diseases with a proactive attitude toward public health challenges. In August 2024, the World Health Organization (WHO) declared Mpox as a public health emergency of international concern due to an upsurge of Mpox cases in the Democratic Republic of the Congo (DRC). To effectively tackle this situation, the United Nations International Children's Emergency Fund (UNICEF) signed an agreement with Bavarian Nordic A/S, under which the MVA-BN Mpox vaccine would be made available to 77 low and lower-middle-income countries at the lowest price in the market. Moreover, in September 2024, WHO initiated funding of USD 58.8 million to deliver treatment for controlling the outbreak of Mpox in Burundi, Central African Republic (CAR), DRC, Kenya, Rwanda, and Uganda. These countries have registered around 22,000 cases, with around 60% cases among children under 15 years old and 80% deaths among children.

North America to Dominate Monkeypox (Mpox) Market Share

North America leads the share of the monkeypox market due to several interrelated factors, such as enhanced treatment accessibility, innovation, and new product launches. According to data from the US Centers for Disease Control and Prevention, Mpox cases in the United States have surged to a rate of 511 reported cases, showing a significant increase from 300 thousand cases by March 2023. While current transmission rates remain substantially lower than the tens of thousands reported in 2022, experts warned of potential case increases due to several factors. The expiration of the public health emergency over a year ago has limited federal resources for managing the response.

Additionally, the relatively low vaccination coverage continues to leave a substantial portion of the population at risk, underscoring the urgent need to improve vaccination efforts as transmission risks rise. In April 2024, Bavarian Nordic A/S launched JYNNEOS in the United States, the only FDA-approved Mpox vaccine. The launch has marked a significant expansion of the company’s activities in the highly promising North American market. Moreover, growing awareness about vaccination and the rising target patient population will further fuel the adoption of JYNNEOS in the United States. According to the data published by the Centers for Disease Control and Prevention (CDC), around two million individuals in the United States are considered eligible for vaccination against Mpox in 2024. The data further stated that 60% of this population remains completely unvaccinated, and 15% have received just one dose of the vaccine. Real-world data demonstrate protective immunity to be more robust in vaccinated individuals who received the primary series of two doses, as indicated by the CDC, than in unvaccinated or one-dose recipients.

Download Free Sample Report

Future Market Scenario (2024-2031F)

The future market scenario is influenced by factors that increase demand and investment, such as the growing awareness about infectious diseases. Healthcare systems are gaining a focus on preparedness for outbreaks through increased funding for research, diagnostics, and vaccines. The recent outbreaks have forced the regulatory bodies to hasten their approval processes for monkeypox treatments and vaccines, boosting market dynamics. Several studies that are undergoing clinical trials, for instance, a phase 3 study of Tecovirimat for the Mpox virus, conducted by the National Institute of Allergy and Infectious Diseases (NIAID) to assess the efficacy of Tecovirimat for the treatment of human Mpox virus disease is holding promising outcomes. Moreover, an ongoing safety study of the MVA-BN Vaccine among children between 2-12 years is being conducted by Bavarian Nordic A/S. The study aims to compare the immunogenicity and safety of the MVA-BN vaccine to prevent Mpox, Smallpox, and other Orthopoxvirus Infections. The promising outcomes from such ongoing trials are expected to expand the existing patient base and introduce newer treatment lines, boosting market growth in the forecast years.

Report Scope

“Monkeypox (Mpox) Market Assessment, Opportunities and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global Monkeypox (Mpox) market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.

Report Attribute	Details
Base Year of the Analysis	2023
Historical Period	2017-2022
Forecast Period	2024-2031
Projected Growth Rate	CAGR of 10.33% between 2024 and 2031
Revenue Forecast in 2031	USD 408.16 million
Segments Covered	Treatment, Route of Administration, Distribution Channel
Regions Covered	North America, Europe, South America, Asia-Pacific, Middle East and Africa
Key Companies Profile	Bavarian Nordic A/S, Emergent BioSolutions Inc., SIGA Technologies Inc., Chimerix, Inc., Piramal Enterprises Ltd., Gilead Sciences, Inc., KM Biologics Co, Jiangsu BioPerfectus Technologies Co., Ltd, Hangzhou Testsea Biotechnology Co., Ltd., Quest Diagnostics Incorporated.
Customization Scope	15% free report customization with purchase
Pricing and Purchase Options	Avail the customized purchase options to fulfill your precise research needs
Delivery Format	PDF and Excel through email (subject to the license purchased)

In the report, global monkeypox (Mpox) market has been segmented into the following categories: 

• By Treatment Type
  • Vaccines
• JYNNEOS
• ACAM2000
  • Therapeutic
• Tecovirimat
• Brincidofovir
• Cidofovir
• By Route of Administration
  • Oral
  • Injectable
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others
• By Region
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East and Africa

Key Players Landscape and Outlook

Monkeypox (Mpox) market is highly dynamic, with different players such as Bavarian Nordic A/S, Emergent BioSolutions Inc., and others. Market activity in recent years includes business agreements, collaborations, and regulatory approvals of products. The market fosters several smaller players, collaborating with other players to cater to a larger market.

In September 2022, Emergent BioSolutions Inc. (Emergent) acquired global rights of Tembexa, an oral antiviral treatment for smallpox, from Chimerix, Inc. This acquisition expanded Emergent product offerings and positioned the company alongside Siga Technologies Inc.’s Tpoxx as a potential treatment for monkeypox. The U.S. Biomedical Advanced Research and Development Authority supported the deal, signing a USD 680 million contract and securing 1.7 million Tembexa courses over 10 years.  

Key Players Operating in Global Monkeypox (Mpox) Market are:

• Bavarian Nordic A/S
• Emergent BioSolutions Inc.
• SIGA Technologies Inc.
• Chimerix, Inc.
• Piramal Enterprises Ltd.
• Gilead Sciences, Inc.
• KM Biologics Co
• Jiangsu BioPerfectus Technologies Co., Ltd
• Hangzhou Testsea Biotechnology Co., Ltd.,
• Quest Diagnostics Incorporated.

Markets and Data’s report answers the following questions:

• What is the current and future market size of the product/service in question globally or specific to different countries?
• How are the markets divided into different product/service segments and the market size and growth of each segment?
• What is the market potential of different product segments and their investment case?
• How are the markets predicted to develop in the future and what factors will drive or inhibit growth?
• What is the business environment and regulatory landscape specific to the product/service?

If you can't find what you're searching for or have any custom requirements for global monkeypox (Mpox) market, you may approach our team at info@marketsandata.com.